Korean study tracks safety of approved hemophilia drug
NCT ID NCT06222697
Summary
This study monitors the safety of an already-approved hemophilia A treatment called Jivi (damoctocog alfa pegol) in Korean patients. Researchers will collect real-world data from about 20 patients who are already receiving this medication as part of their regular care. The goal is to better understand any side effects or problems that might occur during routine use of this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many Locations
RECRUITINGMultiple Locations, South Korea
Conditions
Explore the condition pages connected to this study.